HOUSTON - Nexalin Technology, Inc. (NASDAQ:NXL; NXLIW), a developer of neurostimulation products, has announced it is now in compliance with Nasdaq's minimum bid price requirement. The company received notice from the Nasdaq Stock Market on October 31, 2024, confirming that it meets the necessary standard under Nasdaq Rule 5550(a)(2).
Mark White, CEO of Nexalin, expressed the significance of this development, stating, "Regaining compliance with Nasdaq's listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need." He added that this compliance not only drives shareholder value but also enhances investor visibility as the company progresses in clinical research and global regulatory approvals.
Nexalin focuses on addressing the global mental health crisis through its neurostimulation technology, which is designed to be non-invasive and undetectable to the human body. The company's products aim to provide relief for mental health issues by utilizing bioelectronic medical technology to target structures within the mid-brain associated with mental health disorders. Nexalin's next-generation devices, including the Gen-2 15 milliamp neurostimulation device, have been approved in various international markets such as China, Brazil, and Oman.
The company's forward-looking statements indicate plans and expectations for the future, acknowledging that actual events or results may differ due to numerous factors. These statements are made based on current beliefs and projections and may become outdated over time. Nexalin does not commit to updating these statements beyond the date of the press release, except as legally required.
This announcement is based on a press release statement from Nexalin Technology, Inc.
In other recent news, Nexalin Technology, Inc. has seen a flurry of activity. In a recent annual stockholder meeting, shareholders elected five directors to the board and approved an amendment to the company's 2023 Equity Incentive Plan. They also ratified Marcum LLP as the independent registered public accounting firm for the upcoming fiscal year. The company has also announced the departure of Michael Nketiah, Senior Vice President of Clinical, Quality, & Regulatory Affairs, who is leaving to pursue other professional opportunities.
In addition, Nexalin Technology has managed to regain compliance with Nasdaq's stockholders’ equity requirements following a public offering that raised approximately $5.25 million. The company has also met Nasdaq's minimum bid price requirement, as confirmed by the Nasdaq Stock Market.
In terms of product development, Nexalin Technology has made strides in mental health treatment with its Gen-2 15 milliamp neurostimulation device, which has recently been approved in Oman and China. These are the latest developments in Nexalin Technology's ongoing operations.
InvestingPro Insights
Nexalin Technology's recent compliance with Nasdaq's minimum bid price requirement comes amid a period of significant market performance. According to InvestingPro data, the company has seen an impressive 678.12% price total return over the past year, with a particularly strong 291.51% return in the last month alone. This surge in stock price aligns with CEO Mark White's statement about enhancing shareholder value and investor visibility.
However, investors should note that Nexalin's financial fundamentals present a mixed picture. The company's revenue for the last twelve months as of Q2 2024 was just $0.15 million, with a substantial revenue decline of 76.89% during this period. This stark contrast between stock performance and financial metrics underscores the speculative nature of investments in emerging biotech companies like Nexalin.
InvestingPro Tips highlight that Nexalin's stock price movements are quite volatile, which is consistent with the company's current stage of development and recent market performance. Additionally, analysts do not anticipate the company to be profitable this year, reflecting the ongoing investments in research and development typical of biotech firms.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Nexalin Technology, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.